Open AccessPathogenesis, evaluation and pathogenetic therapy of diabetic polyneuropathy
Author(s) -
И. А. Строков,
V. V. Oganov
Publication year - 2021
Publication title -
nevrologiâ, nejropsihiatriâ, psihosomatika
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.157
H-Index - 9
eISSN - 2310-1342
pISSN - 2074-2711
DOI - 10.14412/2074-2711-2021-3-99-106
Subject(s) - polyneuropathy , diabetes mellitus , medicine , oxidative stress , pathogenesis , disease , alpha lipoic acid , life expectancy , clinical trial , diabetic neuropathy , antioxidant , randomized controlled trial , bioinformatics , gastroenterology , endocrinology , population , biology , biochemistry , environmental health
The increase in the number and life expectancy of patients with diabetes mellitus (DM) worldwide determines the high prevalence of late complications of diabetes, including diabetic polyneuropathy (DPN), the most common type of polyneuropathy. Oxidative stress is considered the main reason for the cellular pathology development in diabetes mellitus, which determines the use of antioxidants for the DPN treatment. Alpha-lipoic acid (ALA), a natural fat-soluble antioxidant, is the most effective drug for reducing DPN symptoms. Furthermore, the symptom-modifying effect of ALA has been shown in numerous randomized controlled trials. The article discusses the possible disease-modifying effect of ALA.